Compare · A vs PKI
A vs PKI
Side-by-side comparison of Agilent Technologies Inc. (A) and PerkinElmer Inc. (PKI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and PKI operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A is the larger of the two at $32.36B, about 1.5x PKI ($21.38B).
- A has hit the wire 4 times in the past 4 weeks while PKI has been quiet.
- A has more recent analyst coverage (25 ratings vs 17 for PKI).
- Company
- Agilent Technologies Inc.
- PerkinElmer Inc.
- Price
- $114.57-0.85%
- $115.23-0.88%
- Market cap
- $32.36B
- $21.38B
- 1M return
- +0.01%
- -
- 1Y return
- +5.50%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 1999
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 17
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
PerkinElmer Inc.
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Latest A
- Bloomberg Expands Global Equity Offering with Australia Domestic Equity Indices
- Agilent to Announce Second-Quarter Fiscal Year 2026 Financial Results on May 27
- Agilent Showcases Cancer Research Solutions at AACR 2026
- Amendment: Agilent Technologies Inc. filed SEC Form 8-K: Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits
- Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 4 filed by Henson Meghan
- Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader
- Amendment: SEC Form SCHEDULE 13G/A filed by Agilent Technologies Inc.
- Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
- SEC Form 4 filed by Rataj Sue H.
Latest PKI
- Gonzales Anita covered exercise/tax liability with 119 shares, decreasing direct ownership by 3% to 3,591 units (SEC Form 4)
- Krakowiak Maxwell covered exercise/tax liability with 85 shares, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Klobuchar Michael A was granted 481 shares (SEC Form 4)
- Vandebroek Sophie V. was granted 481 shares (SEC Form 4)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- Singh Prahlad R. exercised 57,039 shares at a strike of $76.83, sold $2,212,480 worth of shares (21,217 units at $104.28) and covered exercise/tax liability with 15,424 shares, increasing direct ownership by 25% to 103,414 units (SEC Form 4)
- Victor Miriame exercised 2,408 shares at a strike of $105.62 and covered exercise/tax liability with 1,030 shares, increasing direct ownership by 15% to 10,470 units (SEC Form 4)